Design, synthesis, and antifungal activities in vitro of novel tetrahydroisoquinoline compounds based on the structure of lanosterol 14α-demethylase (CYP51) of fungi

被引:49
作者
Zhu, Ju [1 ]
Lu, Jiaguo [1 ]
Zhou, Youjun [1 ]
Li, Yaowu [1 ]
Cheng, Jun [1 ]
Zheng, Canhui [1 ]
机构
[1] Second Mil Med Univ, Sch Pharm, Dept Med Chem, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
CYP51; inhibitor; antifungal activity; tetrahydroisoquinoline; design; lanosterol 14 alpha-demethylase (CYP51);
D O I
10.1016/j.bmcl.2006.08.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Novel tetrahydroisoquinoline compounds were designed by coupling structure-based de novo design based on the structure of lanosterol 14 alpha-demethylase (CYP51). The chemical synthesis and the antifungal activities in vitro of them were reported. The results exhibited that all of the lead compounds showed potent antifungal activities, in which compounds 6 and 7 had equal or stronger antifungal activities against five test fungi than that of fluconazole. The studies presented here provided the antifungal lead compounds. The affinity of the lead molecules for CYP51 was mainly attributed to their non-bonding interaction with the apoprotein, which was different from the azole antifungal agents. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5285 / 5289
页数:5
相关论文
共 21 条
[1]   SYNTHESIS OF ISOQUINOLINES .3. A NEW SYNTHESIS OF 1,2,3,4-TETRAHYDROISOQUINOLINES [J].
BOBBITT, JM ;
KIELY, JMN ;
KHANNA, KL ;
EBERMANN, R .
JOURNAL OF ORGANIC CHEMISTRY, 1965, 30 (07) :2247-+
[2]   Prediction of binding constants of protein ligands: A fast method for the prioritization of hits obtained from de novo design or 3D database search programs [J].
Bohm, HJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1998, 12 (04) :309-323
[4]   The treatment of advanced prostate cancer with ketoconazole - Safety issues [J].
Bok, AB ;
Small, EJ .
DRUG SAFETY, 1999, 20 (05) :451-458
[5]  
FROMTILING R A, 1988, Clinical Microbiology Reviews, V1, P187
[6]   Antifungal agents: Chemotherapeutic targets and immunologic strategies [J].
Georgopapadakou, NH ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) :279-291
[7]   Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14α-demethylase of fungi [J].
Ji, HT ;
Zhang, WN ;
Zhang, M ;
Kudo, M ;
Aoyama, Y ;
Yoshida, Y ;
Sheng, CQ ;
Song, YL ;
Yang, S ;
Zhou, YJ ;
Lü, JG ;
Zhu, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) :474-485
[8]   A three-dimensional model of lanosterol 14α-demethylase of Candida albicans and its interaction with azole antifungals [J].
Ji, HT ;
Zhang, WN ;
Zhou, YJ ;
Zhang, M ;
Zhu, J ;
Song, YL ;
Lü, J ;
Zhu, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (13) :2493-2505
[9]   Use of MCSS to design small targeted libraries: Application to picornavirus ligands [J].
Joseph-McCarthy, D ;
Tsang, SK ;
Filman, DJ ;
Hogle, JM ;
Karplus, M .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (51) :12758-12769
[10]   Second-generation azole antifungal agents [J].
Kale, P ;
Johnson, LB .
DRUGS OF TODAY, 2005, 41 (02) :91-105